Tag:
Ratiopharm
Latest Headlines
Latest Headlines
Teva's Q2 revenues flat on European rise, U.S. fall
The good news from Teva Pharmaceutical Industries: Last year's acquisition of Ratiopharm hiked European sales for the second quarter. The not-so-good: A lack of new product introductions and erosion
Actavis taps ex-Ratiopharm chief as CEO
Iceland's Actavis Group didn't succeed in its bid to buy the German generics maker Ratiopharm, but it has nabbed the company's former chief executive. Actavis has chosen the ex-chief of Ratiopharm,
Teva: Frugal, feisty and full of growth plans
Does Teva ( NASDAQ: TEVA ) "just do it better"? You be the judge. In a profile, the New York Times juxtaposes the company's astonishing growth over the last 10 years--growth in sales to $14 billion
Is Pfizer better off without Ratiopharm?
Losing Ratiopharm to Teva Pharmaceutical Industries may have made Pfizer a winner. That's the theory advanced by Motley Fool, which says that to outbid Teva, Pfizer would have had to overpay. And
Teva comes out on top with $5B Ratiopharm bid
And the winner is... Teva. This morning, the generics giant announced that it was buying Ratiopharm for just under $5 billion, beating out Pfizer and Actavis for the German company. Ratiopharm is
Sources: Pfizer to place Ratiopharm bid today
It's coming down to the wire: Ratiopharm bids are due Thursday, and Reuters sources say Pfizer will come to the party early. The world's largest drugmaker is planning to submit its final bid for the
Why is Ratiopharm suddenly so popular?
Are low interest rates prompting the big interest in Ratiopharm? That's one explanation analysts have hit on in trying to explain Pfizer's newfound zeal at the prospect of buying the German generics
Pfizer pledges big investment in Ratiopharm
Pfizer is pushing hard for a Ratiopharm buy, with top execs traveling to Germany over the weekend to press their case. Some news reports say the drugmaker even boosted its offer for the German
Pfizer rejoins Ratiopharm race with $4B bid
There's a brand new plot twist in the Ratiopharm sale saga: Pfizer is reportedly preparing a $4 billion bid, putting it back in the race for the German generics maker. Pfizer had pulled out of the
Actavis lining up Ratiopharm financing
More details are emerging about the final round of bidding for the German generics maker Ratiopharm. Apparently, the Icelandic drugmaker Actavis has the current high bid, and it's hooking up with
